RiddleMSConnorBABeechingNJet al. Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report. J Travel Med2017;24:63-80.
4.
RiddleMSDuPontHLConnorBA.ACG clinical guideline: diagnosis, treatment and prevention of acute diarrheal infections in adults. Am J Gastroenterol2016;111:602-22.
5.
van SonnenburgFTomieporthNWaiyakiPet al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet2000;356:133-4.
6.
DuPontHLSullivanPEvansDGet al. Prevention of traveler’s diarrhea (emporiatric enteritis): prophylactic administration of subsalicylate bismuth. JAMA1980;243:237-41.
7.
SteffenRDuPontHLHeusserRet al. Prevention of traveler’s diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agents Chemother1986;29:625-7.
8.
DuPontHLEricssonCDJohnsonPCet al. Prevention of travelers’ diarrhea by the tablet formulation of bismuth subsalicylate. JAMA1987;257:1347-50.
ZangerPNurjadiDGaborJet al. Effectiveness of rifaximin in prevention of diarrhea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis2013;13:946-54.
11.
FloresJDupontHLJiangZDet al. A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers’ diarrhea in Mexico during the dry season. J Travel Med2011;18:333-6.
12.
Martinez-SandovalFEricssonCDJiangZDet al. Prevention of travelers’ diarrhea with rifaximin in US travelers to Mexico. J Travel Med2010;17:111-7.
13.
ArmstrongAWUlukanSWeinerMet al. A randomized, doubleblind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers’ diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. J Travel Med2010;17:392-4.
14.
DuPontHLJiangZDOkhuysenPCet al. A randomized, doubleblind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med2005;142:805-12.
15.
AlajbegovicSSandersJWAtherlyDERiddleMS.Effectiveness of rifaximin and fluoroquinolones in preventing travelers’ diarrhea (TD): a systematic review and meta-analysis. Syst Rev2012;1:39.
JohnsonPCEricssonCDuPontHLMorganDRBitsuraJMWoodLV. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers’ diarrhea. J Am Med Assoc1986;255:757-60.
18.
EricssonCDDuPontHLMathewsonJJWestMSJohnsonPCBitsuraJA. Treatment of travelers’ diarrhea with sulfamethoxazole and trimethoprim and loperamide. J Am Med Assoc1990;263:257-61.
19.
DuPontHLJiangZ-DBelkind-GersonJet al. Treatment of travelers’ diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide and loperamide alone. Clin Gastroenterol Hepatol2007;5:454-6.
20.
LalaniTMaguireJDGrantEMet al. Epidemiology and self-treatment of travelers’ diarrhea in a large, prospective cohort of department of defense beneficiaries. J Travel Med2015;22:152-60.
21.
HillDR. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. Am J Trop Med Hyg2000;62:585-9.
DuPontHLEriccssonCDFarthingMJet al. Expert review of the evidence base for self-therapy of travelers’ diarrhea. J Travel Med2009;16:161-71.
24.
De BruynGHahnSBorwickA. Antibiotic treatment for travellers’ diarrhea. Cochrane Database Syst Rev2000;3:CD002242.
25.
EricssonCDDuPontHLOkhuysenPCet al. Loperamide plus azithromycin more effectively treats travelers’ diarrhea in Mexico than azithromycin alone. J Travel Med2007;14:312-9.
26.
ThabaneMSimunovicMAkhtar-DaneshNMarshallJK. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol2009;104:2267-74.
27.
PorterCKGloorKCashBDRiddleMS. Risk of functional gastrointestinal disorders in U.S. military following self-reported diarrhea and vomiting during deployment. Dig Dis Sci2011;56:3262-9.
28.
WangLHFangXCPanGZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut2004;53:1096-101.
29.
NealKRHebdenJSpillerR. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ1997;314:779-82.
30.
Schwille-KiuntkeJMazurakNEnckP. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers’ diarrhea. Aliment Pharmacol Ther2015;41:1029-37.
31.
Ouyang-LatimerJJafriSVanTasselAet al. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala and India from 2006 to 2008. Antimicrob Agents Chemother2011;55:874-8.
32.
SteffenRHillDRDuPontHL. Traveler’s diarrhea: a clinical review. JAMA2015;313:71-80.
33.
TisdaleJE. Drug-induced QT interval prolongation and torsades de pointes. Can Pharm J2016;149(3):139-52.
TaylorDNBourgeoisALEricssonCDet al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Am J Trop Med Hyg2006;74:1060.
36.
HongKSKimJS. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol2011;4(4):227-35.
37.
RiddleMSConnorPFraserJet al. Trial evaluating ambulatory therapy of travelers’ diarrhea (TrEAT TD) study: a randomized controlled trial comparing 3 single-dose antibiotic regimens with loperamide. Clin Infect Dis2017;65(12):2008-2017.
38.
TribbleDRSandersJWPangLWet al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis2007;44:338-46.
39.
KuschnerRATrofaAFThomasRJet al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis1995;21:536-41.
